Single-use medical devices group Vygon has launched Surfcath, a catheter to be used for administering surfactant with LISA method for preterm babies with Respiratory Distress Syndrome (RDS).
It features a curved distal tip, aimed to improve manoeuvrability during the placement of the medical device, while eliminating the need for the commonly used Magill forceps. This will ensure smoother application and lower risk of injuries in premature babies.
RDS is a breathing disorder resulting from surfactant deficiency and underdeveloped lungs, primarily occurring in preterm babies. In Europe, it is reported in about 90% of babies born at 24 weeks and 80% of babies born at 28 weeks. A significant part of RDS treatment is surfactant administration. The current preferred method for surfactant administration is the LISA method, using a thin catheter inserted through the vocal cords in order to avoid unnecessary intubation. This can be performed in a number of ways, which commonly require the use of Magill forceps. The design of the new Surfcath device enables healthcare professionals to insert it without the need for these forceps.
François Rochiccioli, executive vice president, Vygon, said: “Premature neonates are at increased risk of a number of conditions, including Respiratory Distress Syndrome, a serious danger in the first few weeks of their lives. At Vygon we develop bespoke single-use medical devices for patients, including the tiniest, and strive to decrease the risks of injuries or discomfort during procedures while using our devices. We are proud of our latest innovation, Surfcath, co-invented with Dr. Kribs from the University Hospital of Cologne (Uniklinik Köln, Germany). This catheter could considerably improve the preemies care, right after birth."
Vygon’s Surfcath will be available from December 2019 in a 6Fr size, suitable for all neonates. The catheter will be available first in Europe and then in the Americas and in the Asia-Pacific region according to the local registration timelines.
